Touro Scholar
Touro College of Osteopathic Medicine (New
York) Publications and Research

Touro College of Osteopathic Medicine (New
York)

2017

Primary Pulmonary MALT Lymphoma Presenting as NonResolving Pneumonia
Asma Iftikhar
Albert Magh
Muhammed Azaz Cheema
Sarah Thappa
Sonu Sahni
Touro College of Osteopathic Medicine (New York), sonu.sahni@touro.edu

See next page for additional authors

Follow this and additional works at: https://touroscholar.touro.edu/tcomny_pubs
Part of the Neoplasms Commons, and the Respiratory Tract Diseases Commons

Recommended Citation
Iftikhar, A., Magh, A., Cheema, M. A., Thappa, S., Sahni, S., & Karbowitz, S. (2017). Primary pulmonary
MALT lymphoma presenting as non-resolving pneumonia. Advances in Respiratory Medicine, 85(4),
202-205.

This Article is brought to you for free and open access by the Touro College of Osteopathic Medicine (New York) at
Touro Scholar. It has been accepted for inclusion in Touro College of Osteopathic Medicine (New York)
Publications and Research by an authorized administrator of Touro Scholar. For more information, please contact
touro.scholar@touro.edu.

Authors
Asma Iftikhar, Albert Magh, Muhammed Azaz Cheema, Sarah Thappa, Sonu Sahni, and Stephen Karbowitz

This article is available at Touro Scholar: https://touroscholar.touro.edu/tcomny_pubs/32

PRACACase
ORYGINALNA
report

Asma Iftikhar1, Albert Magh1, Muhammed Azaz Cheema2, Sarah Thappa3, Sonu Sahni2, 3, Stephen Karbowitz1
1

New York Presbyterian Hospital Queens, Department of Pulmonary, Critical Care and Sleep Medicine New York, USA
Northwell Health System New Hyde Park, New York, USA
3
Touro College of Osteopathic Medicine, Department of Primary Care, New York, USA
2

Primary pulmonary MALT lymphoma presenting as non-resolving
pneumonia
The authors declare no financial disclosure

Abstract
Primary lung lymphoma (PLL) is a rare unilateral or bilateral lung disorder that is challenging to diagnose solely based on clinical
and radiological presentation. PLL may be misdiagnosed as pneumonia or a lung tumor due to non-specific findings. PLL is most
frequently a mucosa-associated lymphoid tissue (MALT) lymphoma, a type of extranodal low-grade B-cell lymphoma most commonly discovered in the gastrointestinal tract. PLL should be considered in the differential diagnosis of non-resolving pneumonias.
Herein we present a case of an 84-year-old patient discovered to have a primary pulmonary MALT lymphoma presenting as
a non-resolving pneumonia causing a clinical challenge.
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Introduction
Primary lung lymphoma (PLL) is a rare disease that encompasses many histologic types of
lymphomas. It accounts for < 1% of all pulmonary neoplasms and only 3–4% of all extranodal non
-Hodgkin’s lymphomas (NHLs) with a median age
of diagnosis in the sixth decade of life [1, 2]. The
most common histological type of PLL are those
arising from mucosa-associated lymphoid tissue
(MALT), which were first described by Isaacson
and Wright in 1983 [2, 3]. Although MALT most
frequently develops in the gastrointestinal tract,
other sites can include the salivary glands, orbits,
and lungs. MALT lymphoma may be associated
with chronic inflammatory conditions and has
been seen with chronic infections as well as autoimmune disorders e.g. Sjögren’s Syndrome [2].
PLL is often asymptomatic; however, patients may
present with non-specific respiratory symptoms

such as cough, shortness of breath, or constitutional symptoms. Herein we describe a case of
primary pulmonary MALT lymphoma presenting
as a non-resolving pneumonia that caused a diagnostic challenge.

Case report
An 84-year-old, African American, non-smoker male with a history of hypertension (HTN) and
benign prostatic hyperplasia (BPH) presented to
his primary care physician with a two-week history of non-productive cough. He denied chest pain
or shortness of breath. The patient was treated
for possible walking pneumonia on an outpatient
basis with doxycycline without resolution of his
symptoms. Patient was then referred to a pulmonologist for further evaluation. He was retreated
with levofloxacin and, again, failed to show
improvement. He was then recommended for an
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Table 1. Initial laboratory findings
WBC

7.35 ( 4.80–10.80 K/ul)

RBC

4.46 (4.50–5.90M/ul)

HGB

12.5(13.5–17.5 g/dL)

HCT

38.2(42–52%)

PLT

398 (150–400 K/ul)

MCV

85.7 (80–100 fL)

ESR

61 (0–25 mm)

Glucose

82 (74–99 mg/dL)

BUN

29.0 (8.0–23.0 mg/dL)

Creatinine

2.14 (0.70–1.20 mg/dL)

Sodium

134 (136–145 mmol/L)

Potassium

4.9 (3.5–5.1 mmol/L)

Chloride

98 (98–107 mmol/l)

Bicarbonate

24 (22–29 mmol/l)

Calcium

Figure 1. Chest X-ray Right upper and middle lobe scarring and atelectasis with cystic changes. Possible raised right hemi-diaphragm

10.0 (8.6–10.4 mg/dL)

Liver function tests
Protein (total)

6.6 (6.4–8.3g/dl)

Albumin

3.8 (3.5 5.2 g/dl)

AST

17 (5–40 U/L)

ALT

16 (5–41U/L)

Alkaline phosphatase

81 (40–130 U/L)

Bilirubin (total)

0.5 (0.0–1.2 mg/dl)

Bilirubin (direct)

0.1 (0.0–0.9 mg/dl)

Bilirubin (indirect)

0.4 ( 0.0–0.9 mg/dl)

outpatient bronchoscopy to rule out other possible infectious or rheumatological etiology to his
symptoms, but the patient refused. His symptoms
continued to persist and worsen with significant
weight loss of nine kilograms over the course of
a year and a half. Due to worsening cough the
patient was sent to the emergency room for expeditious workup. Past medical history revealed
a previous episode of pneumonia successfully
treated with antibiotics approximately 18 months
prior. The patient reported that he was a pharmacist, and denied a history of drug or alcohol use
or exposure to any toxins. There was no known
exposure to Mycobacterium tuberculosis or other
communicable diseases. On examination, patient
was afebrile with stable vital signs, blood pressure (BP) of 137/77 mm Hg, heart rate (HR) of 66,
oxygen saturation (O2sat) of 93%, respiratory rate
(RR) of 16 breaths per minute and a temperature
of 36.5 degrees Celsius. Initial laboratory findings
and liver function tests have been summarized
in Table 1. Lactose dehydrogenase was not me-

Figure 2. Non-contrast CT lung scan of chest Extensive right-sided
airspace opacities with multiple cysts. No air bronchograms

asured. Physical exam was unremarkable except
for bilateral rhonchi on auscultation. Chest X-ray
(Fig. 1) showed features suggestive of scarring,
atelectasis, and cystic changes in the right lung
indicating possible bronchiectasis. Non-contrast
chest CT (Fig. 2) showed a right-sided pleural
effusion and opacity with likely consolidation
suspicious of pneumonia.
Sputum and serological testing was then performed that was negative for bacteria and fungi.
Screenings for atypical pneumonia microorganisms were negative. Sputum acid-fast bacillus
testing and QuantiFERON-TB Gold test were also
both found to be negative. Due to non-resolving
pneumonia and recent reported weight loss, subsequent bronchoscopy was performed. Biopsies
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with a MALT lymphoma in the right lung. The
Ki-67 proliferative index is 10% - 15%. Anti-Pan
Cytokeratin AE1/AE3 fluorophore highlights the
focal LEL.
After discovery of PLL further investigation
for possible other MALT lesions was performed
— ultrasound and computer tomography of the
abdomen were unremarkable. Patient was referred to oncology due the extensiveness of the
disease and surgery was ruled out. The patient
was treated with a chemotherapy regimen of
cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) and rituximab. After 6 cycles
of chemotherapy, positron emission tomography
(PET) revealed the patient to be disease free and
he was followed on an outpatient basis.

Figure 3. Immunohistochemistry, CD20+, B-cell marker

Discussion

Figure 4. Immunohistochemistry, Bcl-2+. B-cell marginal zone lymphoma marker

taken from the right upper and middle lobe showed MALT extranodal marginal zone lymphoma
(MZL) of the bronchial submucosa heavily infiltrated by small-to medium sized lymphoid cells
containing round or oval nuclei with dispersed
chromatin, inconspicuous nucleoli, and moderate
amounts of cytoplasm. Lymphoepithelial lesion
(LEL) was focally present, which is frequently
associated with MALT lymphoma.
Immunohistochemistry demonstrated neoplastic lymphocytes positive for CD20 (B-cell
marker) (Fig. 3) and Bcl-2 (marginal zone lymphoma marker) (Fig. 4). Neoplastic lymphocytes
were negative for Bcl-1 (mantle cell lymphoma
marker), CD3 and CD5 (T-cell markers), CD10
(acute lymphoblastic leukemia marker), CD23
(IgE receptor antibody), CD43 (T-cell activation
marker), and CD56 (natural killer cell marker).
These results demonstrate that this patient’s
diagnosis is a type 2 B-cell lymphoma, consistent
204

Primary lung lymphoma (PLL) is a rare unilateral or bilateral lung disorder defined as clonal
lymphoid proliferation affecting one or both lungs
(parenchyma and/or bronchi) in a patient with
no detectable extrapulmonary involvement at
diagnosis or during the subsequent 3 months [4].
PLL is most frequently a MALT lymphoma:
a type of extranodal low-grade B-cell lymphoma
characterized by proliferation of clonal marginal
zone lymphocytes, which is most traditionally
associated with Helicobacter Pylori found in the
gastrointestinal tract, specifically the stomach [5].
MALT lymphomas (MALTomas) may also develop
due to chronic inflammation or chronic autoimmune diseases e.g. Sjögren’s syndrome [2, 6].
PLL presents a clinical challenge, as physical or
radiological presentation alone is often not enough to make the diagnosis thus requiring a high
index of suspicion, which may help to determine
presence of this rare, indolent disease. PLL, due
to its non-specific signs and symptoms may be
misdiagnosed as pneumonia or a lung tumor. Here
we have described a case of a MALT lymphoma
located primarily in the lung masking itself as
a non-resolving pneumonia.
MALT lymphomas most commonly present
non-specifically with 36-50% of patients being
asymptomatic at the time of diagnosis [7, 8]. 58%
of symptomatic patients most commonly reported
symptoms of dry cough, dyspnea, chest pain, and
hemoptysis; 22% of symptomatic patients report B
type symptoms such as weight loss, fever, and night
sweats [7, 9]. B type symptoms overlapped with
respiratory manifestations creates a clinical conundrum as was seen in our patient. Initial diagnostic
workup in such patients often includes laboratory
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and diagnostic imaging if infectious etiology is
suspected. Radiological examinations have shown
that non specific patchy opacities or mass like consolidation are seen in up to 68% of patients [10].
The management algorithm of PLL typically
follows that of newly discovered masses with
the gold standard being biopsy of the suspicious
mass. Sampling techniques include transthoracic
needle biopsy, transbronchial biopsy, open thoracotomy and wedge resection by thoracotomy [11].
Our case highlights the use of transbronchial
biopsy via bronchoscopy, which is conservative
in the spectrum of tissue sampling procedures.
Often diagnosis is more challenging and requires
more invasive techniques as reported by Cordier
et al. and Ferraro et al. in which 89% and 90%
of patients required an open thoracotomy for
definitive diagnosis of PLL [9, 12].
Supplemental diagnostic techniques such as
bronchoalveolar lavage (BAL) may also be used to
diagnose; however, BAL sensitivity for MALT lymphoma is only 66% [13]. Immunohistochemistry
may also aid in the diagnosis to distinguish MALT
lymphoma from other small B-cell non-Hodgkin’s
lymphomas as it did in this case. B-cell-associated
antigens such as CD19, CD20, CD22, and CD79a
may be expressed in MALT lymphomas.
Treatment options for primary lung MALT
lymphoma treatment are either surgical resection
or chemotherapy regimen of CHOP with rituximab. Surgical intervention with adjuvant chemotherapy is preferred to preserve lung function
[14]. However, PLL is an indolent disease that does
not always require immediate intervention. Most
patients show no growth or spread of lymphoma
for up to 12 months after diagnosis, and have
a median time to progression of 5.6 years [15].
Even without treatment patients have favorable
prognosis. The ten-year survival for MZL is 53%
[12] with no difference in survival rates of unilateral versus bilateral disease [10].

established management protocol. Treatment is
instead guided by expert opinion rather than
evidence based medicine from randomized clinical trials. If clinical suspicion is high, a full
diagnostic workup — possibly including invasive tissue sampling procedures — should be
considered to accurately diagnose PLL patients
as early as possible.

Conflict of interest
The authors declare no conflict of interest.

References:
1.
2.

3.
4.

5.

6.
7.

8.

9.

10.
11.

Conclusion

12.

Primary lung lymphomas are a rare occurrence that are difficult to diagnose. They are
usually asymptomatic with non-specific clinical
manifestations or radiological characteristics.
Non-specific symptoms may lead to difficulty in
diagnosis. Definitive diagnosis of PLL as a MALT
lymphoma is based on histological examination
of surgical tissue biopsies. Treatment options
for patients like the one presented here could
include monitoring progression, surgery, chemotherapy or radiotherapy. There is no current

13.

14.

15.

Miller DL, Allen MS. Rare pulmonary neoplasms. Mayo Clin
Proc. 1993; 68(5): 492–498, indexed in Pubmed: 8386792.
Cadranel J, Wislez M, Antoine M, et al. AIDS-related primary pulmonary lymphoma. Am J Respir Crit Care Med. 1998;
158(4): 1221–1229, doi: 10.1164/ajrccm.158.4.9801057, indexed in Pubmed: 9769285.
Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma.
Cancer. 1983; 52(8): 1410–1416, indexed in Pubmed: 6193858.
Majid N, Kamal ElB, Oncology B, et al. Primary pulmonary
lymphoma: About five cases and literature review. Lung India.
2014; 31(1): 53–55, doi: 10.4103/0970-2113.125909, indexed
in Pubmed: 24669084.
Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori
infection and gastric lymphoma. N Engl J Med. 1994; 330(18):
1267–1271, doi: 10.1056/NEJM199405053301803, indexed in
Pubmed: 8145781.
Isaacson PG. Mucosa-associated lymphoid tissue lymphoma.
Semin Hematol. . 1999; 36(2): 139–147.
Borie R, Wislez M, Thabut G, et al. Clinical characteristics and
prognostic factors of pulmonary MALT lymphoma. Eur Respir J.
2009; 34(6): 1408–1416, doi: 10.1183/09031936.00039309, indexed in Pubmed: 19541720.
Kurtin PJ, Myers JL, Adlakha H, et al. Pathologic and clinical
features of primary pulmonary extranodal marginal zone Bcell lymphoma of MALT type. Am J Surg Pathol. 2001; 25(8):
997–1008, indexed in Pubmed: 11474283.
Cordier JF, Chailleux E, Lauque D, et al. Primary pulmonary
lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest. 1993; 103(1): 201–208, indexed in
Pubmed: 8417879.
Parissis H. Forty years literature review of primary lung lymphoma. J Cardiothorac Surg. 2011; 6: 23, doi: 10.1186/17498090-6-23, indexed in Pubmed: 21371331.
Wannesson L, Cavalli F, Zucca E. Primary pulmonary lymphoma: current status. Clin Lymphoma Myeloma. 2005; 6(3):
220–227, doi: 10.3816/CLM.2005.n.049, indexed in Pubmed:
16354327.
Ferraro P, Trastek VF, Adlakha H, et al. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000; 69(4):
993–997, indexed in Pubmed: 10800781.
Poletti V, Romagna M, Gasponi A, et al. Bronchoalveolar lavage
in the diagnosis of low-grade, MALT type, B-cell lymphoma
in the lung. Monaldi Arch Chest Dis. 1995; 50(3): 191–194,
indexed in Pubmed: 7663488.
Lee S, Kim MJ, Kim JS, et al. Consortium for Improving Survival of Lymphoma (CISL) study group. Phase II study of gemcitabine for treatment of patients with advanced stage marginal
zone B-cell lymphoma: Consortium for Improving Survival
of Lymphoma (CISL) trial. Invest New Drugs. 2010; 28(2):
171–177, doi: 10.1007/s10637-009-9260-6, indexed in Pubmed:
19421710.
Troch M, Streubel B, Petkov V, et al. Does MALT lymphoma of
the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res. 2007;
27(5B): 3633–3637, indexed in Pubmed: 17972528.

www.journals.viamedica.pl

205

